Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (1): 153-160. doi: 10.19723/j.issn.1671-167X.2022.01.024

Previous Articles     Next Articles

Clinical characteristics of influenza pneumonia in the elderly and relationship between D-dimer and disease severity

LI Jia1,XU Yu2,WANG You-ya3,GAO Zhan-cheng3,△()   

  1. 1. Department of Emergency, Peking University People’s Hospital, Beijing 100044, China
    2. Department of Pulmonary and Critical Care Medicine, Beijing Jishuitan Hospital, Beijing 100035, China
    3. Department of Pulmonary and Critical Care Medicine, Peking University People’s Hospital, Beijing 100044, China
  • Received:2020-07-31 Online:2022-02-18 Published:2022-02-21
  • Contact: Zhan-cheng GAO E-mail:zcgao@bjmu.edu.cn
  • Supported by:
    National Science and Technology Major Project for Control and Prevention of Major Infectious Diseases of China(2017ZX10103004)

RICH HTML

 7   

PDF (PC)

122

Abstract:

Objective: To clarify the clinical characteristics of influenza pneumonia in the elderly patients and the relationship between D-dimer and the severity of influenza pneumonia. Methods: In the study, 52 hospitalized patients older than 65 years with confirmed influenza pneumonia diagnosed in Peking University People’s Hospital on 5 consecutive influenza seasons from 2014 were retrospectively analyzed. General information, clinical symptoms, laboratory data, treatment methods and prognosis of the patients were collected. The relationship between D-dimer and pneumonia severity was analyzed, and receiver operating characteristic (ROC) curve was used to evaluate the predictive value of D-dimer. Results: Among the 52 patients, 31 were male (31/52, 59.6%), the average age was (77.1±7.4) years, and 19 of them (36.5%) were diagnosed with severe pneumonia. About 70% patients presenting with fever. In the severe group, the patients were more likely to complain of dyspnea than in the non-severe group (14/19, 73.7% vs. 10/33, 30.3%, P=0.004), severe pneumonia group had higher level of CURB-65 (confusion, urea, respiratory rate, blood pressure, and age>65), pneumonia severity index (PSI), C-reactive protein, urea nitrogen, lactate dehydrogenase, fasting glucose, and D-dimer (P value was 0.004, <0.001, <0.001, 0.003, 0.038, 0.018, and <0.001, respectively), albumin was lower than that in the non-severe group [(35.8±5.6) g/L vs. (38.9±3.5) g/L, t=-2.348, P=0.018]. There was a significant positive correlation between the D-dimer at the first admission and PSI score (r=0.540, 95%CI: 0.302 to 0.714, P<0.001), while a significant negative correlation with PaO2/FiO2 (r=-0.559, 95%CI: -0.726 to -0.330, P<0.001). Area under the curve of D-dimer was 0.765 (95%CI: 0.627 to 0.872). Area under the curve of PSI was 0.843 (95%CI: 0.716 to 0.929). There was no statistically significant difference in test efficacy between the two (Z=2.360, P=0.174). D-dimer level over 1 225 μg/L had a positive predict value for influenza pneumonia in hospital death with a sensitivity of 76.92% and a specificity of 74.36%. Conclusion: Influenza pneumonia in the elderly always has atypical symptoms, dyspnea is a prominent feature in severe cases, D-dimer level is associated with the severity of influenza pneumonia, and greater than 1 200 μg/L has a good predictive value for in-hospital death in the elderly.

Key words: Aged, Influenza, human, Pneumonia, D-dimer

CLC Number: 

  • R563.1

Table 1

Demographic data and clinical characteristics of elderly patients with influenza pneumonia"

Items Total Severe group Non-severe group Statistical value P
Year
October 1, 2014 to March 31, 2015 7 (13.5) 2 (10.5) 5 (15.2) 1.288 0.863
October 1, 2015 to March 31, 2016 7 (13.5) 2 (10.5) 5 (15.2)
October 1, 2016 to March 31, 2017 6 (11.5) 2 (10.5) 4 (12.1)
October 1, 2017 to March 31, 2018 17 (32.7) 8 (42.1) 9 (27.3)
October 1, 2018 to March 31, 2019 15 (28.8) 5 (26.3) 10 (30.3)
Gender (male) 31 (59.6) 12 (63.2) 19 (57.6) 0.156 0.693
Age/years 77.1±7.4 76.3±7.6 77.5±7.4 -0.544 0.589
65-70 12 (23.1) 5 (26.3) 7 (21.2) 0.360 0.853
71-80 21 (40.4) 8 (42.1) 13 (39.4)
80- 19 (36.5) 6 (31.6) 13 (39.4)
Smoking history 16 (30.8) 5 (26.3) 11 (33.3) 0.279 0.598
Drinking history 6 (11.5) 4 (21.4) 2 (6.1) 2.655 0.103
Coexisting diseases
None 7 (13.5) 2 (10.5) 5 (15.2) 0.298 0.862
1-2 25 (48.1) 9 (47.4) 16 (48.5)
3 and above 20 (38.5) 8 (42.1) 12 (36.4)
Category of coexisting diseases
Coronary heart disease 14 (26.9) 6 (31.6) 8 (24.2) 0.330 0.764
Hypertension 21 (40.4) 8 (42.1) 13 (39.4) 0.037 0.538
Pulmonary diseases 19 (36.5) 7 (36.8) 12 (36.4) 0.001 0.972
Diabetes 15 (28.8) 8 (42.1) 7 (21.2) 2.564 0.126
Chronic renal diseases 5 (9.6) 2 (10.5) 3 (9.1) 0.029 0.610
Chronic liver diseases 6 (11.5) 2 (10.5) 4 (12.1) 0.030 0.620
Cerebrovascular diseases 10 (19.2) 3 (15.8) 7 (21.2) 0.228 0.633
Immune disorders 5 (9.6) 0(0) 5 (15.2) - 0.145
Hematological diseases 10 (19.2) 4 (21.1) 6 (18.2) 0.064 0.800
Cancer 11 (21.2) 4 (21.0) 7 (21.2) 0.020 0.638
Clinical characteristics
Fever 36 (69.2) 13 (68.4) 23 (69.7) 0.009 0.924
Pharyngalgia 14 (26.9) 4 (21.1) 10 (30.3) 0.524 0.543
Cough 29 (55.8) 10 (52.6) 19 (57.6) 0.119 0.730
Expectoration 16 (30.8) 6 (31.6) 10 (30.3) 0.009 0.924
Chest discomfort 16 (30.8) 4 (21.1) 12 (36.4) 0.706 0.401
Dyspnea 24 (46.2) 14 (73.7) 10 (30.3) 1.327 0.004
Hemoptysis 3 (5.8) 0(0) 3 (9.1) - 0.291
Vomiting/diarrhea 7 (13.5) 2 (10.5) 5 (15.2) 0.221 0.638
Myodynia 9 (17.3) 2 (10.5) 7 (21.2) 0.962 0.458
Rigor 4 (7.7) 1 (5.3) 3 (9.1) 0.296 0.543
Fatigue 18 (34.6) 4 (21.1) 14 (42.4) 2.443 0.142
Confusion 7 (13.5) 3 (15.8) 4 (12.1) 0.139 0.697
Vital sign on admission
Temperature/℃ 37.2 (36.5, 38.6) 37.8 (36.9, 39.3) 37.0 (36.5, 38.4) -2.294 0.022
Heart rate/(beat/min) 93.6±18.2 103.7±17.1 87.8±16.4 3.315 0.002
Respiratory rate/(time/min) 20 (18, 22) 22 (20, 24) 18 (18, 20) -1.751 0.080
Systolic blood pressure/mmHg 126 (118, 140) 125 (115, 134) 130 (120, 143) -1.201 0.230
Diastolic blood pressure/mmHg 71 (68, 80) 70 (65, 84) 74 (69, 80) -0.326 0.774
Oxygen saturation/% 93 (91, 94) 92 (90, 93) 93 (92, 95) -2.534 0.011
Score on admission
CURB-65 2.0 (1.0, 3.0) 2.0 (1.0, 2.5) 3.0 (2.0, 4.0) -2.711 0.004
PSI 118 (92, 136) 107 (92, 129) 152 (104, 184) -4.108 <0.001

Table 2

Laboratory data within 24 h of admission in elderly patients with influenza pneumonia"

Laboratory data Reference range Severe group Non-severe group Statistical value P
Blood routine
WBC/(×109/L) 3.5-9.5 8.30 (6.83, 14.87) 8.80 (6.50, 11.58) -0.627 0.531
LY/(×109/L) 1.1-3.2 0.60 (0.40, 1.63) 0.92 (0.60, 1.60) -1.407 0.159
Hb/(g/L) 130-175 110.3±29.9 121.2±19.5 -1.600 0.116
PLT/(×109/L) 125-350 156.0 (98.0, 259.0) 179.0 (148.0, 219.5) -1.131 0.258
Biochemistry
AST/(U/L) 9-35 35.0 (16.0, 90.0) 28.0 (17.5, 52.0) -0.875 0.382
ALT/(U/L) 15-40 32.0 (17.0, 61.0) 31.0 (20.5, 57.5) -0.257 0.797
LDH/(U/L) 109-245 285.0 (199.0, 361.0) 176.0 (90.0, 251.0) -2.936 0.003
ALB/(g/L) 40-55 35.8±5.6 38.9±3.5 -2.348 0.018
BUN/(mmol/L) 2.8-7.2 8.8 (5.6, 11.4) 6.0 (4.6, 8.7) -2.072 0.038
CRE/(μmoI/L) 59-104 75.0 (51.0, 88.0) 77.0 (60.5, 89.0) -0.542 0.588
GLU/(mmol/L) 3.3-6.1 6.8 (5.6, 10.4) 5.5 (4.6, 7.0) -2.376 0.018
Aterial blood gas analysis
pH 7.35-7.45 7.47 (7.41, 7.48) 7.44 (7.38, 7.49) -1.276 0.202
PaO2/FiO2/mmHg 400-500 252.4±84.8 333.7±60.9 -4.004 <0.001
PaCO2/mmHg 35-45 35.2±8.5 41.6±10.8 -2.208 0.032
Lac/(mmol/L) <2.5 2.4 (1.8, 3.9) 2.0 (1.0, 3.1) -1.922 0.055
Coagulation function
PT/s 9.4-12.5 11.7 (11.0, 12.8) 12.0 (11.0, 12.9) -2.331 0.200
APTT/s 25.1-36.5 31.4±7.2 30.3±4.5 0.735 0.466
D-dimer/(μg/L) 0-243 908 (627, 1 398) 300 (193, 549) -4.380 <0.001
Inflammatory markers
CRP/(mg/L) 0-10 56.0 (37.8, 78.2) 19.5 (10.5, 37.6) -3.706 <0.001
PCT/(μg/L) <0.01 0.88 (0.16, 1.83) 0.22 (0.12, 0.99) -1.730 0.084
Myocardial injury markers
TnI greater than 2 fold 3/17 (17.6) 3/28 (10.7) 0.440 0.507
BNP greater than 2 fold 4/15 (26.7) 3/28 (10.7) 1.824 0.215

Table 3

Treatment, complications and outcomes of elderly patients with influenza pneumonia"

Items Total Severe group Non-severe group Statistical value P
Onset to admission/d 7.0 (2.3, 8.0) 7.0 (5.0, 9.0) 7.0 (2.5, 9.0) -0.459 0.646
Virus type 0.847 0.838
A/H1N1 17 (32.7) 7 (36.8) 10 (30.3)
A/H3N2 17 (32.7) 5 (26.3) 12 (36.4)
B 14 (26.9) 5 (26.3) 9 (27.3)
Mixed 4 (7.7) 2 (10.5) 2 (6.1)
Onset to antiviral treatment 0.239 0.135
≤48 h 13 (25.0) 7 (36.8) 6 (18.2)
>48 h 39 (75.0) 12 (63.3) 27 (81.8)
Antiviral drug 9.257 0.010
Oseltamivir 45 (86.5) 13 (68.4) 32 (97.0)
Oseltamivir plus Peramivir 4 (7.7) 4 (21.1) 0(0)
Unused 3 (5.8) 2 (10.5) 1 (3.0)
Co-infection
Bacterial 13 (25.0) 9 (47.4) 4 (12.1) 7.989 0.008
Fungus 3 (5.8) 2 (10.5) 1 (3.0) 0.249 0.618
Antibiotics before admission 45 (86.5) 16 (84.2) 29 (87.9) 0.139 0.709
Antibiotic during admission 0.368 0.947
Unused 3 (5.8) 1 (5.2) 2 (6.1)
1 19 (36.5) 7 (36.8) 12 (36.4)
2 26 (50.0) 9 (47.4) 17 (51.5)
≥3 4 (7.7) 2 (10.5) 2 (6.1)
Antifungal 6 (11.5) 3 (15.8) 3 (9.1) 0.530 0.467
Hormonotherapy 23 (44.2) 12 (63.2) 11 (33.3) 4.348 0.037
Respiratory support
Nasal catheter oxygen 48 (92.3) 19 (100.0) 29 (87.9) 2.495 0.114
Mask oxygen 10 (19.2) 3 (15.8) 7 (21.1) 0.228 0.633
Noninvasive ventilation 23 (44.2) 10 (52.6) 13 (39.4) 0.857 0.355
Invasive ventilation 9 (17.3) 9 (47.4) 0(0) - <0.001
Other support modes
CRRT 9 (17.3) 4 (21.1) 5 (15.2) 0.026 0.588
ECMO 3 (5.8) 3 (15.8) 0(0) - 0.044
Complications
ARDS 16 (30.8) 10 (52.6) 6 (18.2) 6.718 0.010
Pneumothorax 4 (7.7) 2 (10.5) 2 (6.1) 0.339 0.561
Shock 9 (17.3) 6 (31.6) 3 (9.1) 2.843 0.092
Acute kidney injury 12 (23.1) 6 (31.6) 6 (18.2) 1.219 0.270
Myocardial injury 6 (11.5) 3 (15.8) 3 (9.1) 0.077 0.782
Liver injury 9 (17.3) 5 (26.3) 4 (12.1) 1.697 0.193
DIC 10 (19.2) 7 (36.8) 3 (9.1) 4.325 0.038
Encephalopathy 3 (5.8) 2 (10.5) 1 (3.0) 0.249 0.618
ICU admission 20 (38.5) 12 (63.2) 8 (24.2) 7.715 0.005
Length of stay/d 13.5 (9.0, 20.0) 14.0 (11.0, 20.0) 10.0 (8.5, 20.0) -1.162 0.245
Death 13 (25.0) 9 (47.4) 4 (12.1) 7.989 0.008

Figure 1

The relation of D-dimer to PSI and PaO2/FiO2 PaO2/FiO2, oxygenation index; PSI, pneumonia severity index."

Figure 2

Receiver operator characteristic curve for D-dimer and PSI to predict in hospital death PSI, pneumonia severity index."

[1] Luliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study[J]. Lancet, 2018, 391(10127):1285-1300.
doi: 10.1016/S0140-6736(17)33293-2
[2] Gefenaite G, Pistol A, Popescu R, et al. Estimating burden of influenza-associated influenza-like illness and severe acute respiratory infection at public healthcare facilities in Romania during the 2011/12-2015/16 influenza seasons[J]. Influenza Other Respir Viruses, 2018, 12(1):183-192.
doi: 10.1111/irv.2018.12.issue-1
[3] Loubet P, Samihlenzi N, Galtier F, et al. Factors associated with poor outcomes among adults hospitalized for influenza in France: A three-year prospective multicenter study[J]. J Clin Virol, 2016, 79:68-73.
doi: S1386-6532(16)30069-5 pmid: 27105315
[4] 中华人民共和国国家健康委员会. 流行性感冒诊疗方案(2018年版修订版)[J]. 中华临床感染病杂志, 2019, 12(1):1-5.
[5] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(4):253-279.
[6] 中华医学会血液学分会血栓与止血学组. 弥散性血管内凝血诊断中国专家共识(2017年版)[J]. 中华血液学杂志, 2017, 38(5):361-363.
[7] Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury[J]. Am J Kindney Dis, 2013, 61(5):649-672.
[8] Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008[J]. Crit Care Med, 2008, 36(1):296-327.
pmid: 18158437
[9] Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: Advances in diagnosis and treatment[J]. JAMA, 2018, 319(7):698-710.
doi: 10.1001/jama.2017.21907
[10] Childs A, Zullo AR, Joyce NR, et al. The burden of respiratory infections among older adults in long-term care: A systematic review[J]. BMC Geriatr, 2019, 19(1):210.
doi: 10.1186/s12877-019-1236-6
[11] Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment[J]. Crit Care, 2019, 23(1):214.
doi: 10.1186/s13054-019-2491-9
[12] Czaja CA, Miller L, Alden N, et al. Age-related differences in hospitalization rates, clinical presentation, outcomes among older adults hospitalized with influenza: U.S. Influenza Hospitalization Surveillance Network(FluSurv-NET)[J]. Open Forum Infect Dis, 2019, 6(7): ofz225.
[13] Matsuno O, Kataoka H, Takenaka R, et al. Influence of age on symptoms and laboratory findings at presentation in patients with influenza-associated pneumonia[J]. Arch Gerontol Geriatr, 2009, 49(2):322-325.
doi: 10.1016/j.archger.2008.11.015
[14] Talbot HK. Influenza in older adults[J]. Infect Dis Clin North Am, 2017, 31(4):757-766.
doi: 10.1016/j.idc.2017.07.005
[15] Aronen M, Viikari L, Kohonen I, et al. Respiratory tract virus infections in the elderly with pneumonia[J]. BMC Geriatrics, 2019, 19(1):111.
doi: 10.1186/s12877-019-1125-z pmid: 30991957
[16] Chung JY, Hsu CC, Chen JH, et al. Shock index predicted mortality in geriatric patients with influenza in the emergency department[J]. Am J Emerg Med, 2019, 37(3):391-394.
doi: 10.1016/j.ajem.2018.05.059
[17] van Asten L, Luna Pinzon A, de Lange DW, et al. Estimating severity of influenza epidemics from severe acute respiratory infections (SARI) in intensive care units[J]. Crit Care, 2018, 22(1):351.
doi: 10.1186/s13054-018-2274-8
[18] Zhou F, Li H, Gu L, et al. Risk factors for nosocomial infection among hospitalised severe influenza A(H1N1)pdm09 patients[J]. Resp Med, 2018, 134:86-91.
doi: 10.1016/j.rmed.2017.11.017
[19] Sahuquillo JM, Menéndez R, Méndez R, et al. Age-related risk factors for bacterial aetiology in community-acquired pneumonia[J]. Respirology, 2016, 21(8):1472-1479.
doi: 10.1111/resp.12851 pmid: 27417291
[20] Daoud A, Laktineh A, Macrander C, et al. Pulmonary complications of influenza infection: A targeted narrative review[J]. Postgrad Med, 2019, 131(5):299-308.
doi: 10.1080/00325481.2019.1592400 pmid: 30845866
[21] Nguyen JL, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality[J]. JAMA Cardiol, 2016, 1(3):274-281.
doi: 10.1001/jamacardio.2016.0433
[22] Kilic H, Kanbay A, Karalezli A, et al. Clinical characteristics of 75 pandemic H1N1 influenza patients from Turkey; risk factors for fatality[J]. Turk J Med Sci, 2015, 45(3):562-567.
doi: 10.3906/sag-1401-111
[23] Ma S, Lai X, Chen Z, et al. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China[J]. Int J Infect Dis, 2020, 96(1):683-687.
doi: 10.1016/j.ijid.2020.05.068
[24] Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19[J]. J Thromb Haemost, 2020, 18(6):1324-1329.
doi: 10.1111/jth.v18.6
[25] Wang ZF, Su F, Lin XJ, et al. Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1)[J]. Thromb Res, 2011, 127(3):198-201.
doi: 10.1016/j.thromres.2010.11.032 pmid: 21216444
[26] Kim MA, Park JS, Lee CW, et al. Pneumonia severity index in viral community acquired pneumonia in adults[J]. PLoS One, 2019, 14(3):e0210102.
doi: 10.1371/journal.pone.0210102
[27] Dominguez-Cherit G, De la Torre A, Rishu A, et al. Influenza A(H1N1pdm09)-related critical illness and mortality in Mexico and Canada, 2014[J]. Crit Care Med, 2016, 44(10):1861-1870.
doi: 10.1097/CCM.0000000000001830 pmid: 27359085
[1] ZHOU Chuan-xiang,ZHOU Zheng,ZHANG Ye,LIU Xiao-xiao,GAO Yan. Clinicopathological study in 28 cases of oral basaloid squamous cell carcinomas [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 62-67.
[2] Fei WANG,Xiang ZHU,Bei HE,Hong ZHU,Ning SHEN. Spontaneous remission of follicular bronchiolitis with nonspecific interstitial pneumonia: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1196-1200.
[3] Hong MENG,Li-na JI,Jing HUANG,Shuang CHAO,Jia-wen ZHOU,Xue-jun LI,Xiao-mei YIN,Li-rong FAN. Analysis of the changes and characteristics of pediatric outpatient visits in a general hospital in Beijing before and after the COVID-19 pandemic [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 952-956.
[4] YOU Peng-yue,LIU Yu-hua,WANG Xin-zhi,WANG Si-wen,TANG Lin. Biocompatibility and effect on bone formation of a native acellular porcine pericardium: Results of in vitro and in vivo [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 776-784.
[5] PENG Shun-zhuang, FU Xi-xi, FENG Xing-lin. Association between education and the onset of disability in activities of daily living in middle-aged and older Chinese adults: The mediator role of social participation [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 549-554.
[6] ZHOU Chuan, MA Xue, XING Yun-kun, LI Lu-di, CHEN Jie, YAO Bi-yun, FU Juan-ling, ZHAO Peng. Exploratory screening of potential pan-cancer biomarkers based on The Cancer Genome Atlas database [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 602-607.
[7] HUANG Li-dong,GONG Wei-yu,DONG Yan-mei. Effects of bioactive glass on proliferation, differentiation and angiogenesis of human umbilical vein endothelial cells [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 371-377.
[8] Jia-li CHEN,Yue-bo JIN,Yi-fan WANG,Xiao-ying ZHANG,Jing LI,Hai-hong YAO,Jing HE,Chun LI. Clinical characteristics and risk factors of cardiovascular disease in patients with elderly-onset rheumatoid arthritis: A large cross-sectional clinical study [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1040-1047.
[9] Fang BAO,Wei-li SHI,Jing HU,Di ZHANG,Dong-han GAO,Yun-xia XIA,Hong-mei JING,Xiao-yan KE,Qing-gang GE,Ning SHEN. Analysis of the correlation between lymphocyte subsets and severity of corona virus disease 19 [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1075-1081.
[10] Xiao-ning YUAN,Qing-yang MENG,Ning SHEN,Yu-xuan LI,Chao LIANG,Man CUI,Qing-gang GE,Xiao-guang LI,Kun TAN,Qian CHEN,Jing WANG,Xiao-yong ZENG. Detection and evaluation of SARS-CoV-2 nucleic acid contamination in corona virus disease 19 ward surroundings and the surface of medical staff’s protective equipment [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 803-808.
[11] Xiao-qiang LIU,Yu LIAO,Yang YANG,Jian-feng ZHOU,Jian-guo TAN. Effects of loupes and microscope on the prosthodontist’s posture from ergonomic aspects [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 948-951.
[12] Qiu WANG,Jin-yu GUO,Hong SUN,Ling WANG,Ju-su YING,Hui-xin LIU. Investigation of protective exposure risk events in nurses against corona virus disease 2019 in Wuhan [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 711-714.
[13] Zhe-bin WANG,Zhi-jie ZHENG. Research on equity and influencing factors of disability among Chinese middle-aged and old people [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 500-505.
[14] Jun LI,Zhan-yue NIU,Yan XUE,Xue-ying SHI,Bo ZHANG,Yuan WANG. Kaposi sarcoma combined with severe ulcerative colitis: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 373-377.
[15] Xiang-song BAI,Long-wei LV,Yong-sheng ZHOU. Tribbles pseudokinase 3 inhibits the adipogenic differentiation of human adipose-derived mesenchymal stem cells [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 1-9.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2001, 33(1): 32 -34 .
[2] . [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 167 -169 .
[3] . [J]. Journal of Peking University(Health Sciences), 2001, 33(4): 335 -338 .
[4] . [J]. Journal of Peking University(Health Sciences), 2001, 33(5): 407 -410 .
[5] . [J]. Journal of Peking University(Health Sciences), 2002, 34(1): 86 -87 .
[6] . [J]. Journal of Peking University(Health Sciences), 2002, 34(4): 337 -341 .
[7] . [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 52 -56 .
[8] . [J]. Journal of Peking University(Health Sciences), 2008, 40(2): 129 -134 .
[9] . [J]. Journal of Peking University(Health Sciences), 2008, 40(3): 258 -261 .
[10] . [J]. Journal of Peking University(Health Sciences), 2008, 40(3): 273 -279 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd